Abstract
Anaphylaxis means “against protection” and is used in a clinical sense to describe a syndrome of clinical features of which the most common is shock secondary to hypotension. The other lifethreatening features are bronchospasm, swelling of the airway and pulmonary edema. In immunological terminology anaphylaxis is used to describe this symtom complex when produced by an IgE or IgG mediated mechanism. The symptom complex can, however, be produced by a number of clinically indistinguishable mechanisms. This review deals in particular with the pathophysiology and treatment of the cardiovascular mechanisms of anaphylaxis.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Da Silva Machado FR, Assem ESK, Ezeamuzle K (1985) Cardiac anaphylaxis Part II: The role of Prostaglandins thromboxanes and leukotrienes in CA. Allergol et Immunopathol 13:335–350
Levi R (1988) Cardiac anaphylaxis: Models, mediators, mechanisms and clinical considerations. In: Marona A et al (eds) Human inflammatory disease. Clinical Immunology, vol 1. Decker, Toronto, Canada, pp 93–105
Bristow MR, Ginsberg R, Harrison DC (1985) Histamine and the human heart: The other receptor system. Am J Cardiol 49:249–251
Waldenhausen E, Keser G, Marquardt B (1987) Der anaphylaktische Schock. Anaesthesist 36:150–158
Fisher MM (1977) Blood volume replacement in acute anaphylactic cardiovascular collapse. Br J Anesth 49:1023–1026
Fisher MM (1986) Clinical observations on the pathophysiology and treatment of anaphylactic cardiovascular collapse. Anesth Intens Care 14:17–21
Moss J, Fahmy NR, Sunder N, et al (1981) Hormonal and hemodynamic profile of an anaphylactic reaction in man. Circulation 63:210–213
Ziegler HK (1978) Sektionsbefund bei Dextranzwischenfall. Medizinische Klinik 73:1089–1090
Hamberger B, Fredholm BB, Farnebo LO (1980) Anaphylaxis and plasma catecholamines. Life Sci 26(18): 1465–1471
Raper RR, Fisher MM (1988) Profound reversible myocardial dysfunction after anaphylaxis. Lancet 1:386–387
Amir S (1988) Anaphylactoid shock: Catecholamine actions in the responses to opoid antagonists. In: Progress in clinical and biological research, vol 264. Perspectives in shock research. Alan Cissine, New York, pp 265–274
Muelleman RL, Pribble JP, Salamone JA (1988) Blood pressure effects of thyrotropin releasing hormone and epinephrine in anaphylactic shock. Am Emerg Med 17:309–313
Zaloga GP, Delacey W, Holmboe E, et al (1986) Glucagon reversal of hypotension in a case of anaphylactoid shock. Ann Intern Med 105:65–66
Bickell WH, Dice WH (1984) Military antishock trousers in a patient with adrenergic-resistant anaphylaxis. Ann Emerg Med 13:189–190
Low RB (1985) MAST and adrenergic-resistant anaphylaxis. Ann Emerg Med 14:373
Fisher MM, Bowey CJ, Ladd-Hudson K (1988) External chest compression in acute asthma: A preliminary study. Crit Care Med (in press)
Fisher MM (1987) Anaphylaxis. Disease a month 33:436–479
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1989 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Fisher, M. (1989). Anaphylactic Shock: Pathophysiology and Implications for Treatment. In: Vincent, J.L. (eds) Update 1989. Update in Intensive Care and Emergency Medicine, vol 8. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-83737-1_37
Download citation
DOI: https://doi.org/10.1007/978-3-642-83737-1_37
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-50879-3
Online ISBN: 978-3-642-83737-1
eBook Packages: Springer Book Archive